These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis. Kong AM, Farahbakhshian S, Pendergraft T, Brouillette MA, Mukherjee B, Smith DM, Sheehan JJ. Curr Med Res Opin; 2017 Oct; 33(10):1869-1877. PubMed ID: 28613952 [Abstract] [Full Text] [Related]
5. Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease. Huang H, Shetty S, Bauer E, Lang K. Curr Med Res Opin; 2018 Jun; 34(6):1021-1027. PubMed ID: 29231750 [Abstract] [Full Text] [Related]
6. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. Bergeson JG, Worley K, Louder A, Ward M, Graham J. J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475 [Abstract] [Full Text] [Related]
8. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population. Grabner M, Peng X, Geremakis C, Bae J. J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969 [Abstract] [Full Text] [Related]
20. A Retrospective Database Study Comparing Diabetes-Related Medication Adherence and Health Outcomes for Mail-Order Versus Community Pharmacy. Schwab P, Racsa P, Rascati K, Mourer M, Meah Y, Worley K. J Manag Care Spec Pharm; 2019 Mar; 25(3):332-340. PubMed ID: 30816817 [Abstract] [Full Text] [Related] Page: [Next] [New Search]